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Adeno-associated virus (AAV) can impair the replication of other viruses. Adeno-associated virus seroprevalences have been
reported to be lower among women with cervical cancer. In-vitro, AAV can interfere with the production of human papillomavirus
virions. Adeno-associated virus-2 DNA has also been detected in cervical cancer tissue, although not consistently. To evaluate the
role of AAV infection in relation to invasive cervical cancer, we performed a nested case–control study within a retrospectively
followed population-based cohort. A total of 104 women who developed invasive cervical cancer on average 5.6 years of follow-up
(range: 0.5 months–26.2 years) and 104 matched control-women who did not develop cervical cancer during the same follow-up
time were tested for AAV and human papillomavirus by polymerase chain reaction. At baseline, two (2%) case-women and three
(3%) control-women were positive for AAV-2 DNA. At the time of cancer diagnosis, 12 (12%) case-women and 3 (3%) matched
control-women were positive for AAV-2 DNA. Persisting AAV infection was not evident. In conclusion, AAV-2 DNA was present in
a low proportion of cervical cancers and we found no evidence that the presence of AAV in cervical smears of healthy women would
be associated with reduced risk of cervical cancer.
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Cervical cancer ranks as the second most common cancer among
women worldwide. Human papillomavirus (HPV) infection has
been established as the main causal factor for cervical cancer
(Munoz et al, 2003; Schiffman and Castle, 2003). During
carcinogenesis, integration of high-risk HPV causes imbalance in
the expression of the viral oncoproteins E6 and E7 which degrades
tumour suppressor genes p53 and retinoblastoma protein (Rb),
respectively (Alazawi et al, 2002). Proposed cofactors to HPV in
cervical carcinogenesis include other sexually transmitted infec-
tions such as Chlamydia trachomatis infection (Koskela et al,
2000), smoking and genetic risk factors (Ghaderi et al, 2002), but
these have not fully explained why some HPV-exposed women
develop cancer and others do not.
Adeno-associated virus is a helper-dependent parvovirus that
needs co-infection with other viruses, such as adenovirus
(Atchison et al, 1965; Henry, 1973), HPV (Hermonat, 1994; Su
and Wu, 1996; Hermonat et al, 1997), vaccinia virus (Schlehofer
et al, 1986) or herpes simplex virus (HSV) (Salo and Mayor, 1979;
Buller et al, 1981) to help its replication. Among all AAV types,
AAV-2 is the common cause of infection in humans (Friedman-
Einat et al, 1997). Adeno-associated virus-2 Rep78 gene inhibits
HPV-induced cell transformation in vitro (Hermonat, 1994;
Hermonat et al, 1997; Zhan et al, 1999), thus suggesting the
inhibition of HPV gene expression by AAV-2. However, Ahn et al
(2006) could not show any significant viral inhibition in all cervical
cancer cell lines by the AAV-2 Rep 78 gene.
An inverse association between seropositivity for AAV-2 and
cervical cancer has been reported (Mayor et al, 1976; Georg-Fries
et al, 1984). However, studies on detection of AAV DNA in cervical
smears or biopsies do not fully support the serological findings.
Several studies detected AAV DNA in cervical samples (Han et al,
1996; Venturoli et al, 2001; Ahn et al, 2003), while others failed to
detect AAV DNA in cervical samples (Strickler et al, 1999; Odunsi
et al, 2000). Coker et al (2001) found that AAV is associated with
reduced risk in high-grade squamous intra epithelial lesion (HSIL),
but not low-grade squamous intraepithelial lesion (LSIL). How-
ever, Ahn et al (2003) found that AAV is not associated with all
stages of cervical precancer and invasive cancer lesions by in situ
hybridisation and immunohistochemistry.
Whether presence of AAV DNA is associated with cervical
cancer risk has not been assessed in an epidemiological controlled
format. The aim of this study was to investigate if AAV-2 infection
was associated with decreased or increased risk for future
development of cervical cancer, using a retrospective, population-
based study design.
MATERIALS AND METHODS
Study base
The study base consisted of the women residing in the Va ¨ster-
botten county in northern Sweden who attended the population-
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gramme. The population in the county was 260472 inhabitants of
whom 130651 were women in 1995. The programme invites
women in the age group of 25–59 years to participate and it has an
attendance rate of 480% since it was introduced in 1969. All
cervical cancer patients are treated at the Umea ˚ University
Hospital and all clinical data are stored in the same hospital.
Similarly, all cytological diagnoses are made and all specimens
stored at the Cytology Laboratory, Umea ˚ University Hospital
(Wallin et al, 1999).
Study design
The study was based on an earlier case–control retrospective study
as described in Wallin et al (1999). Eligible case-women had been
diagnosed with invasive cancer between the years 1969–1995 after
having had at least one normal smear taken, had at least one
additional smear (irregardless of its cytological diagnosis) taken
and had not had any operative treatment of the cervix. A total of
133 eligible case-women were identified by linking the cytological
registry with the Swedish National Cancer Registry. Further
linkage to the pathological registry was made for the retrieval of
histopathological samples for re-review and laboratory analysis.
Four women were excluded due to incorrect entries into the cancer
registry, 12 due to missing histopathological specimens and 11 due
to non-invasive cervical neoplasia, leaving 106 cases of invasive
cervical cancer. Of these two biopsies were inadequate for
polymerase chain reacion (PCR) analysis, leaving 104 cases (85
squamous cell carcinoma and 19 adenocarcinoma), with serial
samples available for the study. Control subjects were women from
the same study base who did not develop cervical cancer during
the same period before the diagnosis of cancer in their
corresponding cases. Each control was matched one to one to its
case according to age and time of sampling of the baseline smears
and existence of normal follow-up smears matched in time of
sampling to the cervical cancer biopsies. Thus, each case-woman
contributed a normal smear taken before invasive cancer diagnosis
and a histological sample with a confirmed diagnosis of cervical
carcinoma, and each control woman contributed two normal
smears matched to the normal smear and biopsy of its
corresponding case. The mean time between the sampling of the
baseline smear and cancer diagnosis was 5.6 years (range: 0.5
months–26.6 years). The average age at which the baseline smear
was obtained was 44 years (range: 19–74) among the women with
cancer and 44 years (range: 20–74) among the control-women.
The dates of the smears of the women with cancer and those of the
control-women differed by 1 month, on average. The subsequent
smears of the control-women were typically obtained after the
diagnosis of cancer in the corresponding women with cancer, as
absence of disease in the controls for at least the same duration of
follow-up was an essential component of the study design. If a
control-woman had several normal smears after the date of the
diagnosis of cancer in the corresponding woman with cancer, the
smear obtained on the date closest to the date of the diagnosis of
cancer was chosen. The time of biopsy in the woman with cancer
and the time the smear was obtained in the corresponding
control-woman differed by up to 10 months. The average age of the
women with cancer at the time of diagnosis was 50 years (range:
24–79), and the average age of the control-women at the time of
the second normal smear was 50 years (range: 24–79) (Wallin
et al, 1999).
All cytological smears and histological slides were re-evaluated
before laboratory analysis. Ethical approval was obtained from the
Institutional Review Board of Umea ˚ University. As decided by the
Institutional Review (IRB): Umea ˚ University (2003-02-11, 98/03,
Dnr 98-12), information about the study was made known to the
public that donated the samples by press conferences.
DNA extraction from paraffin sections and archival Pap
smears
DNA was extracted from archival smears and biopsies as described
earlier (Chua et al, 1996). In brief, coverslips of Pap smears were
removed with xylene and the cytoplasmic stain was removed in
95% ethanol. A mild lysis buffer containing 25ml of proteinase K
(20mgml
 1) (Sigma, Sigma-Aldrich, Hamburg, Germany) per
1.0ml of buffer was used to dislodge the cells off the glass slide,
and the cells were pipetted into a sterile Eppendorf tube. An
additional 10ml of proteinase K was added and digestion was
carried out at 55–601C for a minimum of 2h. Protein was
precipitated by the addition of 100ml saturated ammonium acetate,
and centrifuged at 14000rpm at room temperature for 5min. DNA
was precipitated using cold ethanol and dissolved in low EDTA,
tris-EDTA (TE) buffer.
Four 5mm-thick sections were taken from each paraffin block.
Knives were changed and an empty paraffin block sectioned in
between each biopsy to prevent cross-contamination. The fifth
section was stained with haematoxylin and eosin for review to
ensure that the proceeding sections contained tumour tissue for
PCR analysis. Deparaffinization was carried out in xylene and the
tissue rehydrated through graded alcohols, then air-dried and
digested with buffer containing 10ml proteinase K (20mgml
 1).
Digestion was carried out at 601C for a minimum of 2h until a
clear lysate was obtained. Heating the samples at 981C for 10min
inactivated proteinase K.
All samples were tested for DNA integrity by PCR using human
ribosomal gene S14 primers, which gave 150bp amplimers. The
blank sections were tested by S14 PCR to check for contamination
during sectioning.
Adeno-associated virus polymerase chain reaction
As positive control, DNA extracted from HA-16 cells (kindly
donated by Professor JR Schlehofer) was used. It is a cervical
cancer cell line HeLa (containing HPV 18) transfected with AAV-2
(Walz and Schlehofer, 1992). These cells were grown in DMEM
medium (PAA laboratories GmbH, Austria) supplemented with
10% fetal calf serum (FCS), streptomycin (50mgml
 1) and
penicillin (500Uml
 1) and DNA was extracted for PCR. DNA
was extracted according to the standard protocols and measure-
ments were made by UV-1601spectrophotometer (Shimadzu,
Japan).
Three primer pair sets were chosen for AAV detection. (1) The
pan 1/pan 3 primer pairs are general primers for AAV-2, -3 and -5
which have a size of 338bp (Tobiasch et al, 1998). A sensitive panel
was set up for pan AAV PCR, in which total HA-16 DNA
concentration varied at 50, 100, 250 and 500pg. Negative controls
for AAV consisted of DNA extraction from HeLa cell line, and
blanks containing no DNA were also included. The detection limit
for the pan-AAV primers PCR system was 100pg total HA-16
DNA. (2) Non-nested AAV-2 primers (Han et al, 1996) and (3)
AAV-nested PCR (Mehrle et al, 2004), both AAV-2 PCR systems,
target the AAV-2 rep gene. They were tested against a sensitive
panel total HA-16 DNA with DNA concentration ranging from
230ng to 0, 23pg. The detection limit for non-nested AAV-2 PCR
system was 23pg while that of nested AAV-2 was 2, 3pg.
Oligonucleotide primers used in this study are detailed in Table 1.
Optimisation of the PCR reactions was tested at different
annealing temperatures, primer concentrations and MgCl2 con-
centrations. DNA amplification was performed in a 50ml reaction
mix containing 1.0–3.0ml of template DNA, and for second round
nested PCR, 5ml of the first round of PCR product was used as
template DNA, 1 PCR buffer, 1.5–2.0mM MgCl2, 0.2mM of each
of dATP, dCTP, dTTP, dGTP (Roche, Germany), 10pmol of each of
pan-AAV or AAV-2 primers, respectively, 5ml of 2% BSA and 1.0–
1.5U Taq DNA polymerase (Promega, Madison WI, USA).
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sPolymerase chain reactions were performed using Peltier Thermol
Cyclerb PTC-100 (MJ Research, Inc. Waltham, MA, USA). The PCR
reaction consisted of 40 cycles with the denaturation step at 941C
for 30s, followed by the annealing step at 621C for pan-AAV or
641C for non-nested AAV-2 or 621C for nested AAV-2 PCR,
respectively, for 30s and extension at 721C for 45s. Each PCR was
initiated by one denaturation step at 951C for 1min before the
amplification cycles and completed by one extension step at 721C
for 5min after 40 amplification cycles. A volume of 10ml PCR
products were loaded into 2% agarose gel and visualised with
ethidium bromide. Positive PCR products were sequenced
according to the protocol for ABI Prismt BigDyet Terminator
Cycle Sequencing Ready Reaction Big Dye Terminators Kit kit
(Perkim Elmer Applied Biosystems, Foster City, CA, USA). Blanks
containing no DNA were included as contamination controls.
Varying amounts of template DNA was used on repeated PCR runs
to overcome the effect of inhibitors present in the DNA extraction.
To test the specificity of the AAV PCR systems, different PCR
primer sets directed towards pan-AAV, AAV-2 (nested or non-
nested) and HPV amplification were tested on DNA from HA-16
cells (contain HPV 18 and AAV-2), SiHa cells (contain HPV 16)
and HeLa cells (contain HPV18).
Human papillomavirus polymerase chain reaction
The HPV consensus primers MY09/MY11 and GP5þ/6þ were
used in single-tube nested PCR, where the GP5þ/6þ products
were amplified in abundance for gel electrophoresis and HPV
typing by DNA sequencing. Details of the procedure had been
published (Wallin et al, 1999). The PCR analyses were performed
blind to cases or controls and were analysed at the same time, to
avoid the risk of assay performance variation. The sensitivity of the
PCR system was based on dilutions of HPV-16 L1 plasmids (1 copy
to 500 copies) mixed with 2ml of DNA extracts from 10 HPV PCR-
negative cervical smears as a check for PCR inhibition. Dilutions of
(1fg–10pg) DNA extracts from HPV-16-positive SiHa cervical
cancer cell-line were also included into each PCR run as a
sensitivity panel. DNA from HPV-16-positive CaSki and HPV-
negative C33A cervical cancer cell-lines were also included as
controls (Wallin et al, 1999).
HPV DNA typing
Human papillomavirus typing was performed first with type-
specific primers for HPV-16 (E1: 1768–1960) and HPV-18 (E7:
591–900) as described (Evander et al, 1991). Samples that were
HPV-positive by general primers but negative by type-specific
primers were subjected to DNA sequencing of the GP5þ/6þ
amplimers according to the ABI Prismt BigDyet Terminator
Cycle Sequencing Ready Reaction Big Dye Terminators Kit (PE
Applied Biosystems, Perkim-Elmer Corp., Foster City, CA, USA)
and sequenced using the ABI 310 sequencer (PE Applied
Biosystems).
Statistical analysis
Relative risk with 95% confidence interval (CI) was estimated as
odds ratio (OR) by logistic regression using epiinfo software (Epi
Info 2000, Centers for Disease Control and Prevention, Atlanta,
Georgia, USA).
RESULTS
The PCR primer specificity test showed a positive band using the
pan-AAV and the two AAV-2 PCR systems with HA-16 DNA but
not when SiHa or HeLa cell DNA was used as template. HPV
general primers gave a positive band when all three cervical cancer
cell-lines were tested, which is expected as they all contain HPV
DNA.
The level of sensitivity for the three PCR systems used in this
study was 2.3pg HA-16 DNA for nested AAV-2, 23pg for non-
nested AAV-2 and 100pg for pan-AAV. The detection limits were
repeatable and consistent in each PCR run for each system. The
S14 PCR, which was incorporated to test the amplifiability of DNA,
was positive in all samples tested in this material. To overcome
possible intrinsic inhibition of PCR amplifications, three different
rounds of PCR of the entire study material were repeated using
1–3ml of template DNA.
For pan-AAV PCR, AAV DNA was not detectable in any of the
baseline smears and their corresponding matched controls, nor in
the cervical cancer biopsies. The non-nested AAV-2 PCR system
detected AAV DNA in one cervical cancer biopsy and one control
smear matched to a cancer biopsy. With the nested AAV-2 PCR,
2/104 (2%) of the prediagnostic smears of cancer cases and 3/104
(3%) of the prediagnostic smears of matched control-women were
positive for AAV DNA. At cancer diagnosis, 12/104 (11.7%) of
biopsies with cancer were positive and 3/104 (3%) of matched
control smears to the biopsies were positive for AAV DNA (OR for
cancer in case of AAV DNA positivity: 4.39 (95% CI: 1.11–20.29).
Persisting AAV infection in the same woman was not found in any
one of the women in our study (Table 2). Results of the HPV DNA
testing have been reported previously (Wallin et al, 1999). In brief,
HPV DNA status at baseline among cytologically normal smears
for cases was 29.8% (31/104) as compared to 2.8% (3/104) among
controls. Seventy-seven percent (80/104) had HPV DNA in the
cervical cancer biopsies. Of these case-women, 27 had persistent
HPV DNA at both the baseline smear and the cancer biopsy, while
only one control-woman was HPV DNA-positive in her baseline
smear and her second smear, thus conferring an increased risk of
58.7 (95% CI: 10.2–N) (Wallin et al, 1999).
When we compared the presence of AAV-2 DNA with HPV DNA
of the same sample in the entire study material, none of the
Table 1 Oligonucleotide primers used in this study
Type Primer sequence Position Length in bp
Pan AAV 50-AAC TGG ACC AAT TGA AAA CTT TCC-30 338
50-AAA AAG TCT TTG ACT TCC TGC TT-30
Non-nested AAV-2 50-CAT CGC GGA GGC CAT AGC CC-30 1346–1365 221
50-ACG GGA GTC GGG TCT ATC TG-30 1548–1567
Nested AAV-2 50-ACA CCA TCT GGC TGT TTG GG-30 1303–1323 337
50-GGC TGC TGG TGT TCG AAG GT-30 1640-1620
50-GAG GCC ATA GCC CAC ACT GT-30 1353–1373 151
50-GAG AAT GGC TTT GGC CGA CT-30 1483–1504
S14 50-CAG TGA CAT GGA CAA AAG TG-30 150
50-TCG AAA GGG GAA GGA AAA GA-30
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while 10 biopsy case samples had both AAV and HPV DNA. None
of the matched control smears were positive for both viruses.
Ninety-seven samples were both negative for HPV and AAV-2
(Table 3).
DISCUSSION
Adeno-associated virus–2 is considered a common infection
worldwide in both adults and children with seroprevalence from
30 to 60% according to a study done involving individuals from
Germany, Brazil and Japan (Erles et al, 1999). Furthermore, AAV
has been postulated to be sexually transmitted as AAV DNA had
been isolated from cervical samples, semen, spontaneously aborted
material and gestational human trophoblasts (Atchison et al, 1965;
Tobiasch et al, 1994; Kiehl et al, 2002).
It was suggested from previous seroepidemiological studies that
AAV infection could protect women against the development of
cervical cancer (Mayor et al, 1976). However, there were other
studies that showed no significant difference between the
seroprevalence for AAV among cases and controls, although lower
antibody titers among cancer patients than among non-cancer
patients were seen (Georg-Fries et al, 1984; Strickler et al, 1999;
Smith et al, 2001).
DNA-based analysis on clinical samples taken from the cervix
has reported inconsistent results regarding AAV and cervix cancer.
Some studies detected high prevalence AAV-2 DNA in cervical
samples (Han et al, 1996; Ahn et al, 2003). However, others found
that AAV prevalence was not high in cervical tissue (Grossman
et al, 1992; Strickler et al, 1999; Odunsi et al, 2000). Based on our
optimised and sensitive PCR systems, a low proportion of samples
were found positive are well in line with the reports of absence or
low prevalence of AAV, irrespective of the nature of the samples
(Grossman et al, 1992; Odunsi et al, 2000).
Experimentally, in-vitro co-infection of AAV and HPV may
involve complex molecular/biological interactions that result in
either the repression or promotion of HPV replication. In-vitro
experiments using organotypic ‘raft’ culture system, which enable
epithelial cells to reach terminal differentiation and thereby
support the complete HPV life cycle indicated that when AAV-2
was present at low multiplicity of infection (MOI), HPV replication
was slightly increased. The reverse was seen at high AAV MOI.
Thus, suggesting that AAV may have a significant effect upon the
kinetics of HPV life cycle regulation in the natural host tissue,
where the exact mechanism behind the interaction effect is still
largely unknown (Meyers et al, 2001; Agrawal et al, 2002).
Our study base is a population-based cohort of healthy women
who did or did not develop cervical cancer on follow-up. It is a
reliable study design to evaluate possible risk factors. The study
design using closed cohorts with comprehensive case assessment
actually has minimal risks for selection biases. All Pap smears
analysed in our study were cytological normal, and the baseline for
AAV DNA prevalence among case-women was low (2%), as
compared to 3% among control-women. The low prevalence in our
study material could be influenced by the nature of the specimen.
Fixed and stained samples often present with degradation of DNA.
To overcome any technical problem, the PCR systems used had
been carefully optimised, validated with variable template volumes
used to overcome the effect of inhibition. Furthermore, the PCR
products produced were within the range suitable for amplification
by PCR from archival DNA. However, biopsies contain more cells
as compared to smears and that could have contributed to greater
success in amplifying AAV DNA. The detection limits for the PCR
systems we used were similar for both biopsy and Pap smear.
Despite the higher AAV DNA prevalence among the invasive
cancers (11%) as compared to the matched smears from control-
women, the data suggest an association but a larger sample
population utilizing fresh smears or biopsies should be ideal.
In conclusion, we found a low proportion of cervical cancer
biopsies contain AAV-2 genomes. In addition, AAV DNA
persistence was not detectable in our longitudinal study. Adeno-
associated virus-2 infection cannot be associated with decreased or
increased risk for future development of cervical cancer.
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